Efficiency of using the probiotic «Linex for children» in infants with acute respiratory viral diseases

Abstract

The efficacy of the probiotic "Linex for children" containing bifidobacteria to maintain the intestinal microflora and local intestinal immunity was studied in infants with acute respiratory viral infection (ARVI). All children received antibiotic therapy for evolving bacterial complications; 20 children from a study group were given the probiotic "Linex for children" along with antibiotics; 20 comparison group children with the same disease did not take the probiotic. Treatment with the probiotic did not deteriorate the intestinal microflora. Two thirds of the examined children showed improvement in the microflora composition, including normal biocenosis achievement. In the comparison group, the intestinal microflora was deteriorated in most children (и=15) and unchanged only in three. During the treatment of ARVI, the fecal slgA concentration increased in both groups, but after a probiotic cycle, it was significantly higher than in the comparison group (145,1+5,49 and 107,1+4,5 mg/g feces, respectively; /КО,05). The use of the probiotics also caused a six-fold increase in lysozyme concentrations in the coprofiltrate up to 33,8+2,30 ug/ml and no change in this indicator in the comparison group. It is expedient to use the probiotic "Linex for children" in infants with ARVI to prevent impairments in the intestinal microflora and local intestinal immunity during antibacterial therapy.